NAYA
NAYA Biosciences, Inc. Common StockNAYA
NAYA
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
2.45% less ownership
Funds ownership: 7.0% [Q3] → 4.55% (-2.45%) [Q4]
15% less capital invested
Capital invested by funds: $194K [Q3] → $165K (-$29.3K) [Q4]
25% less funds holding
Funds holding: 12 [Q3] → 9 (-3) [Q4]
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$24
908%
upside
Avg. target
$24
908%
upside
High target
$24
908%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Maxim Group Jason McCarthy 26% 1-year accuracy 9 / 35 met price target | 908%upside $24 | Buy Upgraded | 23 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025
SARASOTA, Fla. and MIAMI, March 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, and a leading provider of in vitro fertilization (IVF) and in vivo Intravaginal Culture (“IVC”) fertility treatments, announced today that it will effect a 1-for-12 reverse split of its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on March 18, 2025. Commencing with the opening of trading on The Nasdaq Capital Market on March 18, 2025, the Company's common stock will trade on a post-split basis under the same trading symbol, “NAYA”.
Neutral
GlobeNewsWire
1 month ago
NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment
NAYA Sees Potential Positive Impact to Its Existing Fertility Operations and FDA-Cleared INVOcell Technology NAYA Sees Potential Positive Impact to Its Existing Fertility Operations and FDA-Cleared INVOcell Technology
Neutral
GlobeNewsWire
1 month ago
NAYA Biosciences Announces Nomination of New Board Members
SARASOTA, Fla. and MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women's health, today announced that its board of directors has nominated five new candidates with extensive experience in in the biotechnology industry to be approved at the company shareholder meeting scheduled for March 10th, 2025.
Charts implemented using Lightweight Charts™